Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2007 1
2010 3
2011 2
2013 8
2014 8
2015 16
2016 17
2017 15
2018 24
2019 21
2020 26
2021 33
2022 26
2023 8
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 31915996

181 results

Results by year

Filters applied: . Clear all
Page 1
Edoxaban versus warfarin in vitamin K antagonist experienced and naïve patients from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial.
Kozieł M, Al-Saady N, Hjortshøj SP, Goudev A, Huber K, Cohen A, Jin J, Melino M, Winters SM, Goette A, Lip GYH. Kozieł M, et al. Clin Res Cardiol. 2020 Aug;109(8):1018-1024. doi: 10.1007/s00392-019-01594-9. Epub 2020 Jan 8. Clin Res Cardiol. 2020. PMID: 31915996 Free PMC article. Clinical Trial.
Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
Goette A, Merino JL, Ezekowitz MD, Zamoryakhin D, Melino M, Jin J, Mercuri MF, Grosso MA, Fernandez V, Al-Saady N, Pelekh N, Merkely B, Zenin S, Kushnir M, Spinar J, Batushkin V, de Groot JR, Lip GY; ENSURE-AF investigators. Goette A, et al. Lancet. 2016 Oct 22;388(10055):1995-2003. doi: 10.1016/S0140-6736(16)31474-X. Epub 2016 Aug 30. Lancet. 2016. PMID: 27590218 Clinical Trial.
A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.
Lip GY, Merino J, Ezekowitz M, Ellenbogen K, Zamoryakhin D, Lanz H, Jin J, Al-Saadi N, Mercuri M, Goette A. Lip GY, et al. Am Heart J. 2015 May;169(5):597-604.e5. doi: 10.1016/j.ahj.2015.02.009. Epub 2015 Feb 21. Am Heart J. 2015. PMID: 25965706 Free article. Clinical Trial.
Relation of Stroke and Bleeding Risk Profiles to Efficacy and Safety of Edoxaban for Cardioversion of Atrial Fibrillation (from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation [ENSURE-AF] Study).
Lip GYH, Merino JL, Dan GA, Themistoclakis S, Ellenbogen KA, De Caterina R, Goudev A, Jin J, Melino M, Winters SM, Goette A. Lip GYH, et al. Am J Cardiol. 2018 Jan 15;121(2):193-198. doi: 10.1016/j.amjcard.2017.10.008. Epub 2017 Nov 20. Am J Cardiol. 2018. PMID: 29169605 Free article. Clinical Trial.
Anticoagulation Control in Warfarin-Treated Patients Undergoing Cardioversion of Atrial Fibrillation (from the Edoxaban Versus Enoxaparin-Warfarin in Patients Undergoing Cardioversion of Atrial Fibrillation Trial).
Lip GYH, Al-Saady N, Jin J, Sun M, Melino M, Winters SM, Zamoryakhin D, Goette A. Lip GYH, et al. Am J Cardiol. 2017 Sep 1;120(5):792-796. doi: 10.1016/j.amjcard.2017.06.005. Epub 2017 Jun 15. Am J Cardiol. 2017. PMID: 28709650 Free article. Clinical Trial.
181 results